Please login to the form below

Not currently logged in
Email:
Password:

Pneumococcal vaccine

This page shows the latest Pneumococcal vaccine news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Pfizer’s Prevnar-13 successor takes aim at Merck rival

Pfizer just got a leg-up in its race with Merck &Co to bring a new-generation pneumococcal vaccine to the US market after getting a breakthrough designation (BTD) for its ... is in pursuit of PCV-15 (also known as V114), a 15-valent candidate that Merck

Latest news

  • Pfizer's Prevenar 13 price cut slammed by MSF Pfizer's Prevenar 13 price cut slammed by MSF

    Pfizer has reduced the price of its pneumococcal vaccine Prevenar 13 for an immunisation programme targeting low-income countries, but has been criticised for not going far enough. ... However, medical charity Medecins Sans Frontieres (MSF) said the

  • CHMP thumbs up for Novo's obesity drug Saxenda CHMP thumbs up for Novo's obesity drug Saxenda

    Prevenar 13 also backed. Meanwhile, the CHMP has also issued a positive opinion for an application by Pfizer to extend the indications for its pneumococcal vaccine Prevenar 13 to include the ... prevention of pneumonia caused by the 13 pneumococcal

  • Call for GSK and Pfizer to reduce vaccine price Call for GSK and Pfizer to reduce vaccine price

    Call for GSK and Pfizer to reduce vaccine price. MSF campaigns to lower cost of pneumococcal shot to $5 per child in developing countries. ... with the Reach Every Child conference that will bring leading vaccine donors together in Berlin next week.

  • US panel backs pneumococcal vaccines for seniors US panel backs pneumococcal vaccines for seniors

    Adults over 65 who have not previously received pneumococcal vaccine - or whose previous vaccination history is unknown - should receive a dose of Prevnar 13 first, followed by a dose of Pneumovax ... The ACIP decision comes shortly after European

  • Pfizer closes on $1bn label expansion for Prevenar Pfizer closes on $1bn label expansion for Prevenar

    Pfizer closes on $1bn label expansion for Prevenar. EMA begins review of the pneumococcal vaccine. ... European regulators have started their review of Pfizer's application to market pneumococcal vaccine Prevenar 13 more widely in adults, which could

More from news
Approximately 1 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    26.6. ‡ SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV).

  • A tailored approach to the BRIC markets A tailored approach to the BRIC markets

    In 2009, GSK signed a 1.5bn deal with the Brazilian government to provide Syflorix, its vaccine for paediatric pneumococcal disease, at around a third of the price it charged in ... Europe. The deal guaranteed GSK a set price and set volumes for the

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics